Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has demonstrated significant operating margin expansion, with expectations of over 16% improvement and an increase of at least 750 basis points, indicating strong financial performance. The company’s momentum is supported by promising tailwinds, including the adoption of its Organ Care System (OCS) and anticipated growth in organ transplant volumes, which are projected to rise approximately 35.2% year-over-year in Q4. Additionally, the company is poised for robust revenue growth, with estimated U.S. sales reaching $163.9 million, reflecting a 40.5% increase year-over-year, surpassing previous consensus estimates.

Bears say

TransMedics Group Inc. has experienced a concerning decline in key operational metrics, such as a decrease in daily flights and flight hours, which have fallen to levels similar to those recorded in the first quarter of 2025. Despite reporting an increase in product revenues of 33.1% year-over-year, the company fell approximately $1 million short of consensus expectations, which may negatively impact its stock performance. Furthermore, the company's reliance on successful product introductions and its struggles to expand and scale its salesforce present significant commercialization risks, exacerbated by competitive pressures and potential regulatory challenges.

TMDX has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 8 analysts, TMDX has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $144.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $144.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.